Clinical trial
Chloroquine as an Anti-autophagy Drug in Stage IV Small Cell Lung Cancer (SCLC) Patients: A Phase 1 Trial
NCT00969306 is registered in ClinicalTrials.gov with Maastricht Radiation Oncology as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Chloroquine as an Anti-autophagy Drug in Stage IV Small Cell Lung Cancer (SCLC) Patients: A Phase 1 Trial
- Lead sponsor
- Maastricht Radiation Oncology
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- September 30, 2013
- Completion date
- June 30, 2016
- Enrollment
- 5 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
small cell lung cancer